Drug Treatments for Skin Disease Introduced in 2005

Drug Class	Generic/Trade Company Names	Indication	Approving Regulatory Agency
Antiaging Treatments	Clindamycin Foam 1% Aluma®Skin Renewal System with FACES™ Lumenis	Approved for the noninvasive treatment of fine lines and wrinkles.	US FDA
Antibacterial Agents	Meropenem for Injection MERREM® AstraZeneca	Approved for the noninvasive treatment of fine lines and wrinkles.	US FDA
	Moxifloxacin HCl Avelox® Bayer HealthCare Schering-Plough	Approved for the treatment of complicated skin and skin structure infections in adults and children.	US FDA
	Tygacycline Tygacil® Wyeth	Approved for the treatment of complicated skin and skin structure infections in adults that are caused by methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae.	US FDA EMEA
Antifungal Agents	Ciclopirox Topical Suspension 0.77% Taro Pharmaceuticals	Abbreviated NDA approved for the treatment of fungal infections of the skin. It is the bioequivalent of Medicis Pharmaceutical’s Loprox® Topical Suspension 0.77%.	US FDA
	Griseofulvin Oral Suspension USP Glades Pharmaceuticals	Approved for the treatment of tinea barbae, tinea capitis, tinea corporis, tinea pedis, and tinea unguium (onychomycosis).	US FDA
	Terbinafine HCl Lamisil®Tablets Ranbaxy Laboratories	Approved for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium).	US FDA
Antihistamine	Desloratadine Syrup Clarinex®Reditabs® Schering-Plough	Reformulated 2.5mg and 5mg tablets approved for the treatment of allergy symptoms caused by both perennial indoor and seasonal outdoor allergens and for chronic idiopathic urticaria, or hives of unknown cause, in adults and children >6 years of age.	US FDA
Antipruritic Agents	Epinastine HCl 1% Alesion®Dry Syrup Nippon Boehringer Ingelheim/ Sankyo	Approved for the treatment of allergic rhinitis, urticaria, and pruritus associated with skin diseases such as eczema and dermatitis in pediatric patients.	Japanese Ministry of Health, Labour and Welfare
Antipsoriatic Agents	Clobetasol Propionate 0.05% Clobex™Spray Galderma	For the treatment of moderate-to-severe plaque psoriasis. Clobex® is already available as a lotion and shampoo.	US FDA
	Efalizumab Raptiva® Serono	Approved for the treatment of moderate-to-severe chronic plaque psoriasis in adults >18 years of age who are candidates for systemic therapy or phototherapy.	TPD Canada
	Etanercept Enbrel® Amgen/ Wyeth Pharmaceuticals	Approved for the treatment of moderate-to-severe psoriasis in adults.	TPD Canada
	Fluocinonide 0.1% Vanos® Cream Medicis Pharmaceuticals	A new class I topical corticosteroid approved for the treatment of plaque-type psoriasis affecting up to 10% of the body surface area.	US FDA
	Infliximab Remicade® Centocor/ Schering-Plough	Approved for the treatment of moderate-to-severe plaque psoriasis in adults who failed to respond to, or have a contraindication to, or are intolerant of other systemic therapies including cyclosporine, methotrexate, or PUVA.	EMEA
Atopic Dermatitis Agents	Fluticasone Propionate 0.05% Cutivate®Lotion Pharmaderm/Altana	Approved in patients >1 year of age for the treatment of atopic dermatitis.	US FDA
	Hydrogel Dressing MimyX®Cream Stiefel Laboratories	A topical nonsteroidal cream approved for the treatment of atopic dermatitis.	US FDA
HIV/AIDS	Emtricitabine Emtriva™Oral Solution Gilead Sciences	Approved for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients >3 months of age.	US FDA
	Tipranavir Capsule Aptivus® Boehringer Ingelheim Pharmaceuticals	Accelerated approval for this nonpeptide protease inhibitor as a combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, and who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors. The approved dose is 500mg taken with 200mg ritonavir twice daily	US FDA EMEA
Leishmaniasis	Miltefosine Impavido™ AEterna Zantaris	Approved for the treatment of the cutaneous form of leishmaniasis as well as the visceral form of this condition.	Columbian Food and Drug Agency
Oncologic Agents	Imiquimod 5% Aldara™Cream 3M	Approved for the treatment of superficial basal cell carcinoma.	TPD Canada
Psoriatic Arthritis Agents	Adalimumab Humira™ Abbott Laboratories	Approved for the treatment of psoriatic arthritis.	US FDA
	Etanercept Enbrel® Amgen/ Wyeth Pharmaceuticals	Approved for the improvement of physical function in patients with psoriatic arthritis.	US FDA
	Infliximab Remicade® Centocor/ Schering-Plough	Approved for the treatment of psoriatic arthritis.	US FDA
Rosacea	Metronidazole Topical Gel 1% MetroGel® Galderma Laboratories LP	Approved for the topical treatment of inflammatory lesions of rosacea.	US FDA
Vaccines	Measles, Mumps, Rubella, and Varicella Virus Vaccine, Live ProQuad® Merck	Approved for simultaneous vaccination against measles, mumps, rubella, and varicella in children 12 months to 12 years of age.	US FDA EMEA
Wound Management	Antimicrobial Barrier Dressing ACTICOAT* Moisture Control Smith & Nephew	Approved for wound care as a barrier to bacterial penetration, featuring the patented Silcryst™ nanocrystalline silver technology.	US FDA

1. A Practical Guide to Dermatological Drug Use in Pregnancy
2. Drug Treatments for Skin Disease Introduced in 2005
3. Update on Drugs and Drug News - May 2006